RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos(Icahn School of Medicine at Mount Sinai), David B. Solit(Memorial Sloan Kettering Cancer Center), Manickam Janakiraman(Memorial Sloan Kettering Cancer Center), Thomas G. Graeber(Exicure (United States)), Roger S. Lo(University of California, Los Angeles), Keith T. Flaherty(Cancer Research Center), Gatien Moriceau(APLA Health), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Bjoern Titz(Roche (Switzerland)), Kimberly B. Dahlman(Vanderbilt University), Madhavi Tadi(Memorial Sloan Kettering Cancer Center), Neal Rosen(Memorial Sloan Kettering Cancer Center), May Tal Gabay(Memorial Sloan Kettering Cancer Center), Hubing Shi(Sichuan University), Xiangju Kong(University of California, Los Angeles), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Antoni Ribas(University of California, Los Angeles), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Mohammad Atefi(Namazi Hospital), Charles Ng(University of California, Los Angeles), Mark C. Kelley(Vanderbilt University), Maayan Salton(Hebrew University of Jerusalem), Tom Misteli(National Cancer Institute), Yogindra Persaud(Memorial Sloan Kettering Cancer Center)
Cited by 1,438
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k